drugset
drugset / Trial / NCT05498597

AMT-151 in Patients With Selected Advanced Solid Tumours

NCT05498597 ↗

Phase 1 Unknown 30 enrolled Multitude Therapeutics Inc. Tigermed Consulting Co., Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.

Timeline

Start
2023-01-25
Primary completion
2024-01-01
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-151 Unknown — Intravenous

Indications

endometrial clear cell adenocarcinoma endometrial endometrioid adenocarcinoma endometrial serous adenocarcinoma lung adenocarcinoma malignant pleural mesothelioma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma pancreatic ductal adenocarcinoma triple-negative breast carcinoma